Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo GnRH antagonist Clear all
Active, not recruiting Phase 3 Interventional

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
44
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Outcomes of Low Testosterone

NCT02758431
View directory record Official record
Conditions
Hypogonadism
Interventions
Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 23, 2026, 6:02 PM EDT
Active, not recruiting Phase 3 Interventional

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

NCT06375811
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
Elagolix 200 MG, Placebo or SOC IVF
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196
View directory record Official record
Conditions
Menopause, Aging
Interventions
KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT02677896
View directory record Official record
Conditions
Metastatic Hormone Sensitive Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
34
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 23, 2026, 6:02 PM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

NCT05726292
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 23, 2026, 6:02 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

NCT03112226
View directory record Official record
Conditions
Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction, Vascular Stiffness
Interventions
GnRHant + E2, GnRHant + Placebo
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 23, 2026, 6:02 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 23, 2026, 6:02 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
View directory record Official record
Conditions
Heart Diseases, Left Ventricular Dysfunction
Interventions
Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

NCT01327495
View directory record Official record
Conditions
Healthy
Interventions
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 23, 2026, 6:02 PM EDT
Terminated Phase 2 Interventional Results available

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

NCT02582749
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions
LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
Drug · Radiation
Lead sponsor
Ajjai Alva, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

NCT01215292
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis

NCT04173169
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
Elagolix 200 MG, Placebo or SOC IVF
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 23, 2026, 6:02 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Bioenergetic Effects of Aging and Menopause (BEAM)

NCT04043520
View directory record Official record
Conditions
Menopause, Obesity, Abdominal, Aging, Weight Gain
Interventions
GnRH antagonist, Estrogen Product, Placebo estradiol, Placebo GnRH antagonist
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 23, 2026, 6:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Steroids in Obese Men

NCT00983554
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Anastrazole, Testosterone, Dutasteride, GnRH antagonist
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
24 Years to 51 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 2 Interventional

Endometriosis Trial: Study of NBI-56418 in Endometriosis

NCT00109512
View directory record Official record
Conditions
Endometriosis
Interventions
NBI-56418 (GnRH antagonist), placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Phoenix, Arizona • San Diego, California • San Ramon, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 23, 2026, 6:02 PM EDT
Completed Phase 2 Interventional Results available

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

NCT04743934
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Flibanserin 100 MG, Placebo, Androgen deprivation therapy
Drug
Lead sponsor
Andrew McDonald
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 23, 2026, 6:02 PM EDT